Drug intelligence / Profile preview

BR1019

Development stage: Unknown
Lead developer: Boryung
Modality: Small Molecules
Administration: Oral

Overview

BR1019 is an orally administered small molecule drug candidate being developed by Boryung Pharmaceutical for the treatment of hypertension and type 2 diabetes mellitus. It is classified as both an antihyperglycaemic and antihypertensive agent. The precise mechanism of action has not been defined in public sources. As of early 2025, it has reached phase III clinical trials for hypertension and type 2 diabetes mellitus in South Korea[1][2][3]. Clinical studies have also evaluated its pharmacokinetics and safety profile in healthy volunteers[7].

Other names: BR1019A-1BR-1019A-1BR 1019A-1BR1019 1BR-1019 1BR 1019 1BR1019ABR-1019ABR 1019A

Targets

SGLT2 (Sodium-glucose cotransporter protein subunit 2)AGTR1 (Angiotensin II Type-1 receptor)

Beyond the preview

Go deeper on BR1019.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BR1019.

Explore the full profile